

POSLUMA® Recommended Dose and Administration Instructions¹

Recommended Dose

The recommended amount of radioactivity to be administered in adults is 296 MBq (8 mCi) as an intravenous bolus injection.

Preparation and Administration Instructions

- Inspect POSLUMA visually for particulate matter and discoloration before administration. Do not use the drug if the solution contains particulate matter or is discolored.
- Use aseptic technique and radiation shielding when withdrawing and administering POSLUMA.
- Calculate the necessary volume to administer based on calibration time and required dose.
- The recommended maximum volume of undiluted POSLUMA is 5mL.
- POSLUMA may be diluted with 0.9% Sodium Chloride Injection, USP.
- Assay the dose in a dose calibrator before administration.

Post Administration Instructions

- After the POSLUMA injection, administer an intravenous flush of sterile 0.9% Sodium Chloride Injection, USP to ensure full delivery of the dose.
- Dispose of any unused drug in a safe manner in compliance with applicable regulations.

Dosimetry

The effective radiation dose resulting from the administration of the recommended activity of 296 MBq of POSLUMA is:

4.1 mSv¹

For the recommended activity of 296 MBq (8mCi), the radiation absorbed doses to critical organs is as follows:

- Adrenals: 54.3 mGy (0.184 mGy/MBq)
- Kidneys: 51 mGy (0.172 mGy/MBq)
- Submandibular glands: 43.8 mGy (0.148 mGy/MBq)

When PET/CT is performed, the exposure to radiation will increase by an amount dependent on the settings used in the CT acquisition¹

Abbreviations:

USP, United States Pharmacopeia.

References:

1. POSLUMA® (flotufolastat F 18) Injection. US Prescribing information; Blue Earth Diagnostics, Ltd. May 2023.